Galmed says Aramchol-Xtandi combo lifts prostate cancer cell death 3-4 fold in preclinical study

Galmed disclosed first-time preclinical prostate cancer results for Aramchol combined with Xtandi, with results already presented.

• The combination produced stronger tumor cell killing than Xtandi alone, supporting a potential role in delaying treatment resistance.
• Strategic focus targets Xtandi’s multibillion-dollar franchise as key patents expire in Europe in 2026 and the US in 2027.
• Management framed the regimen as a lifecycle-management option ahead of a planned US price cut starting in 2027.
• Partnering talks are planned based on a recently submitted patent application covering the Aramchol-enzalutamide combination.